EU Pharma Package: New Sunshine Disclosure Rules
Author
Sabrina Morgan is the Head of Global Compliance & Customer Delivery at Vector Health. She oversees global transparency reporting and international disclosure requirements along with the Italian Sunshine Act strategy. She also leads the global client delivery team dedicated to data integrity, compliance solutions, and regulatory alignment for pharmaceutical and MedTech organizations.
Vector Health Compliance
Your Leading Partner in Global Sunshine Compliance
Recent Blogs
Europe has never had a single Sunshine Act. Transparency around payments and other transfers of value to healthcare professionals (HCPs) and organisations has grown country by country: France with the Loi Bertrand, Italy with Law 62/2022 and its national register, and many other markets relying on the industry-led EFPIA Disclosure Code. The result is a patchwork, and some Member States have no statutory regime at all.
The EU pharmaceutical reform now moving through its final stages is set to put a floor under that patchwork. For life sciences companies, it is worth understanding early, even though it is not yet law.
Where the EU pharma package stands
The European Parliament and the Council reached provisional agreement on the pharma package in December 2025. The Council formally adopted its position at first reading on 28 September 2026, and the text is now with the European Parliament for second reading. The chair of Parliament’s public health committee has signalled that the committee will recommend approving the Council’s position without amendments. If Parliament does so, the package is adopted without a further Council vote and can be published in the Official Journal. As of 4 November 2026 the plenary vote has not yet taken place: the committee is due to vote its recommendation on 10 November, and the plenary vote is expected in November.
The package has two parts: a Regulation, which applies directly in every Member State, and a Directive, which Member States must transpose into national law. The disclosure provision discussed here sits in the Directive, so it will only take effect through national transposition. As a general rule, Member States will have around two years to transpose the Directive, which on current expectations points to late 2028 or later. The Regulation follows its own application dates, including transitional phases.
What the new disclosure provision requires
Article 189 of the Council’s first-reading position (numbering may change in final publication) addresses Member States that have no national rules governing the disclosure of transfers of value. Earlier drafts, such as the March 2026 compromise text, cited the provision as Article 186(4a). In those countries, the national authority must establish and maintain, on its national medicines web-portal, a publicly available list of links to disclosure platforms. These platforms are operated either by trade associations or by marketing authorisation holders (MAHs), and they cover transfers of value linked to the advertising activities regulated elsewhere in the same legislation.
Two features stand out:
- It is a fallback, not a national Sunshine Act. Countries that already have rules are not the target. The provision fills the gap where none exist, by pointing the public to existing industry disclosure platforms.
- Accountability sits with the MAH. The text states that MAHs must provide the necessary weblinks and remain responsible for the accuracy and timely publication of the disclosed information. Read alongside the reference to platforms run by trade associations, this suggests that responsibility stays with the MAH even where an association hosts the platform, although national implementation will confirm how this works in practice.
A related change sits in the same advertising chapter. The new Directive reportedly removes the “minimal value” exception and prohibits incentives to healthcare professionals (Article 183 in the March compromise numbering), while still allowing hospitality at promotional events within strict limits. That narrows what can be offered and, in turn, what ends up being disclosed.
What this does not do
It is important not to overstate the change. The provision does not create a harmonised EU-wide register, a single reporting template or a common data model. It does not replace national regimes such as the Italian Sunshine Act or the French Loi Bertrand. An earlier proposal from Parliament would have obliged Member States to set up an actual transparency register themselves; the compromise replaced that with the list of platform links, so transparency remains a national competence. What the provision does is establish a minimum expectation that, anywhere in the EU, the public can find disclosures of transfers of value through an official national entry point.
Transposition: slow, and not uniform
Because the disclosure provision sits in the Directive, the practical effect will arrive through national law. Transposition can take years, and both the timing and the detail of national rules may differ by country. Companies should not assume a uniform start date or a uniform approach across the EU.
Why this matters for compliance teams
For companies already reporting in France, Italy and other regulated markets, the headline impact may look limited. The real new exposure is elsewhere:
- MAHs outside an association platform. Companies that are not members of an EFPIA-affiliated association, or that operate in markets where no disclosure platform exists, may disclose nothing today. Under this provision, a Member State without national rules must list platforms run by trade associations or by MAHs, so these companies may need to make their transfers of value available through a platform of their own and supply the link.
- Wider footprint. Activity in Member States without a statutory regime, often handled informally today, will need to be tracked and published through a recognised platform.
- Data quality as a legal responsibility. If the MAH answers for accuracy and timeliness, weak data feeds are a compliance exposure. Multi-ERP environments and inconsistent spend coding make this harder.
- HCP identity matching. Accurate attribution of transfers of value depends on matching HCP and HCO records across systems and countries, including national identifiers where they exist.
- Data protection. Publishing personal data of HCPs has to be reconciled with GDPR, including the lawful basis for publication and the rules on transfers of personal data outside the EEA.
- Audit readiness. Regulators and platform operators may expect a clear trail from source transaction to published record.
How to prepare now
- Map your footprint. List the Member States where you operate and identify which have a national disclosure regime and which do not.
- Assess data readiness. Check whether you can consolidate transfer-of-value data from every ERP and local system into one reconciled, auditable dataset.
- Review platform access. Understand which trade association or company platforms would be used in markets without national rules, and who owns the publication process internally.
- Watch the legislative calendar. Track the Parliament vote, publication in the Official Journal and national transposition bills, and update your plans as the final text and local timelines emerge.
The bottom line
The EU pharma package will not give Europe a single Sunshine Act, but it will narrow the gaps. Existing regimes show where the weak point usually lies. When France’s Court of Audit reviewed the Loi Bertrand transparency system a few years after it was passed, it identified the lack of any verification of the declared information as one of its major flaws. Disclosure rules are only as credible as the data behind them. The earlier transfer-of-value data is centralised, validated and traceable, the easier each new obligation becomes to absorb, and a single, reliable source of truth for global transfers of value is the most practical preparation, whatever the final national rules look like.
This article is for informational purposes only and does not constitute legal advice. The legislative text is not yet final and may change before adoption.
Europe has never had a single Sunshine Act. Transparency around payments and other transfers of value to healthcare professionals (HCPs) and organisations has grown country by country: France with the Loi Bertrand, Italy with Law 62/2022 and its national register, and many other markets relying on the industry-led EFPIA Disclosure Code. The result is a patchwork, and some Member States have no statutory regime at all.
The EU pharmaceutical reform now moving through its final stages is set to put a floor under that patchwork. For life sciences companies, it is worth understanding early, even though it is not yet law.
Where the EU pharma package stands
The European Parliament and the Council reached provisional agreement on the pharma package in December 2025. The Council formally adopted its position at first reading on 28 September 2026, and the text is now with the European Parliament for second reading. The chair of Parliament’s public health committee has signalled that the committee will recommend approving the Council’s position without amendments. If Parliament does so, the package is adopted without a further Council vote and can be published in the Official Journal. As of 4 November 2026 the plenary vote has not yet taken place: the committee is due to vote its recommendation on 10 November, and the plenary vote is expected in November.
The package has two parts: a Regulation, which applies directly in every Member State, and a Directive, which Member States must transpose into national law. The disclosure provision discussed here sits in the Directive, so it will only take effect through national transposition. As a general rule, Member States will have around two years to transpose the Directive, which on current expectations points to late 2028 or later. The Regulation follows its own application dates, including transitional phases.
What the new disclosure provision requires
Article 189 of the Council’s first-reading position (numbering may change in final publication) addresses Member States that have no national rules governing the disclosure of transfers of value. Earlier drafts, such as the March 2026 compromise text, cited the provision as Article 186(4a). In those countries, the national authority must establish and maintain, on its national medicines web-portal, a publicly available list of links to disclosure platforms. These platforms are operated either by trade associations or by marketing authorisation holders (MAHs), and they cover transfers of value linked to the advertising activities regulated elsewhere in the same legislation.
Two features stand out:
- It is a fallback, not a national Sunshine Act. Countries that already have rules are not the target. The provision fills the gap where none exist, by pointing the public to existing industry disclosure platforms.
- Accountability sits with the MAH. The text states that MAHs must provide the necessary weblinks and remain responsible for the accuracy and timely publication of the disclosed information. Read alongside the reference to platforms run by trade associations, this suggests that responsibility stays with the MAH even where an association hosts the platform, although national implementation will confirm how this works in practice.
A related change sits in the same advertising chapter. The new Directive reportedly removes the “minimal value” exception and prohibits incentives to healthcare professionals (Article 183 in the March compromise numbering), while still allowing hospitality at promotional events within strict limits. That narrows what can be offered and, in turn, what ends up being disclosed.
What this does not do
It is important not to overstate the change. The provision does not create a harmonised EU-wide register, a single reporting template or a common data model. It does not replace national regimes such as the Italian Sunshine Act or the French Loi Bertrand. An earlier proposal from Parliament would have obliged Member States to set up an actual transparency register themselves; the compromise replaced that with the list of platform links, so transparency remains a national competence. What the provision does is establish a minimum expectation that, anywhere in the EU, the public can find disclosures of transfers of value through an official national entry point.
Transposition: slow, and not uniform
Because the disclosure provision sits in the Directive, the practical effect will arrive through national law. Transposition can take years, and both the timing and the detail of national rules may differ by country. Companies should not assume a uniform start date or a uniform approach across the EU.
Why this matters for compliance teams
For companies already reporting in France, Italy and other regulated markets, the headline impact may look limited. The real new exposure is elsewhere:
- MAHs outside an association platform. Companies that are not members of an EFPIA-affiliated association, or that operate in markets where no disclosure platform exists, may disclose nothing today. Under this provision, a Member State without national rules must list platforms run by trade associations or by MAHs, so these companies may need to make their transfers of value available through a platform of their own and supply the link.
- Wider footprint. Activity in Member States without a statutory regime, often handled informally today, will need to be tracked and published through a recognised platform.
- Data quality as a legal responsibility. If the MAH answers for accuracy and timeliness, weak data feeds are a compliance exposure. Multi-ERP environments and inconsistent spend coding make this harder.
- HCP identity matching. Accurate attribution of transfers of value depends on matching HCP and HCO records across systems and countries, including national identifiers where they exist.
- Data protection. Publishing personal data of HCPs has to be reconciled with GDPR, including the lawful basis for publication and the rules on transfers of personal data outside the EEA.
- Audit readiness. Regulators and platform operators may expect a clear trail from source transaction to published record.
How to prepare now
- Map your footprint. List the Member States where you operate and identify which have a national disclosure regime and which do not.
- Assess data readiness. Check whether you can consolidate transfer-of-value data from every ERP and local system into one reconciled, auditable dataset.
- Review platform access. Understand which trade association or company platforms would be used in markets without national rules, and who owns the publication process internally.
- Watch the legislative calendar. Track the Parliament vote, publication in the Official Journal and national transposition bills, and update your plans as the final text and local timelines emerge.
The bottom line
The EU pharma package will not give Europe a single Sunshine Act, but it will narrow the gaps. Existing regimes show where the weak point usually lies. When France’s Court of Audit reviewed the Loi Bertrand transparency system a few years after it was passed, it identified the lack of any verification of the declared information as one of its major flaws. Disclosure rules are only as credible as the data behind them. The earlier transfer-of-value data is centralised, validated and traceable, the easier each new obligation becomes to absorb, and a single, reliable source of truth for global transfers of value is the most practical preparation, whatever the final national rules look like.
This article is for informational purposes only and does not constitute legal advice. The legislative text is not yet final and may change before adoption.
Author
Sabrina Morgan is the Head of Global Compliance & Customer Delivery at Vector Health. She oversees global transparency reporting and international disclosure requirements along with the Italian Sunshine Act strategy. She also leads the global client delivery team dedicated to data integrity, compliance solutions, and regulatory alignment for pharmaceutical and MedTech organizations.
Vector Health Compliance
Your Leading Partner in Global Sunshine Compliance



